Intensity-modulated radiation therapy: Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
Temozolomide: Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.
1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female subjects ≥ 18 years of age
* Must be newly diagnosed with GBM
* Primary treatment must consist of a chemoradiation therapy (CRT) regimen
* Hemoglobin \> 9 g/dL
* White blood count 3,600 - 11,000/mm3
* Absolute neutrophil count (ANC) ≥ 1,500/mm3
* Absolute lymphocyte count (ALC) ≥ 1,000/mm3
* Platelet count 100,000/mm3
* BUN ≤ 1.5 times upper limit of normal
* Creatinine clearance rate \> 40 mL/min
* ALT ≤ 3 times upper limit of normal
* AST ≤ 3 times upper limit of normal
* Alkaline phosphatase ≤ 3 times upper limit of normal
* Total bilirubin ≤ 2.0 mg/dL
* Karnofsky Performance Status ≥ 70
* Must not be on any other alternative therapies
* Not pregnant
Exclusion Criteria:
* Known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their derivatives or components
* Known allergy to vitamin A, vitamin D3, and/or L-citrulline
* Pregnant women
* Breastfeeding women
* Corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of dexamethasone or its equivalent
* History of immunodeficiency diseases or autoimmune diseases
* History of peptic ulcer disease or gastrointestinal perforation
Primary outcome measure(s)
Number of participants with treatment-emergent adverse events and serious adverse events — 1 month Safety and tolerability of NG101m as adjuvant therapy to chemoradiation therapy
Efficacy of NG101m adjuvant chemoradiation therapy assessed by measuring 2-year overall survival rate. — 24 months Efficacy of NG101m adjuvant therapy will be assessed by measuring 2-year overall survival rate.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.